Idraparinux

Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug. a synthetic analogue of the pentasaccharide sequence in heparins. It is grouped under the following drug class(es): Antithrombotic agents. Its therapeutic use is listed as anticoagulants and cardiovascular. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include sr34006. Its PubChem CID is 3083445.

CAS No 162610-17-5
Molecular Formula C38H64O49S7
Molecular Weight 1529.4 g/mol
Synonyms (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6-[(2R,3S,4S,5R,6R)-2-carboxy-4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(sulfooxymethyl)oxan-2-yl]oxyoxane-2-carboxylic acid

Frequently Asked Questions